Asthma is a rare phenomenon in modern medicine; in spite of technological advances, improvement in mortality rates have not been demonstrated. Instead, asthma mortality has been steadily increasing over the past thirty years, especially in inner city, African-American, and pediatric populations. 2, 3 The mortality risk is not reflected in any of the current systems used for categorizing asthma severity. In fact 30% of all patients who die from asthma have been characterized as mild asthmatics just prior to their fatal exacerbation. Furthermore, bronchial biopsy and bronchoalveolar lavage studies have shown inflammatory changes in the airways of cases of mild asthma, even at times when there was no asthma exacerbation. 3, 4 Thus it appears that, at least as far as mortality risk and ongoing inflammation are concerned, there is nothing mild about "mild asthma".
Increasing asthma mortality, wide exposure of all asthma severity groups (including mild and moderate) to fatal outcome, and evidence of persistent inflammation during remission of asthma symptoms are the challenges for all current asthma severity classifications. Dr. Colice's review highlights the pathology of asthma as an inflammatory disease, the discrepancy between the severity of asthma symptoms and the severity of ongoing, underlying inflammation, and the need for regular clinical assessment of asthma control. Colice concludes with the need for developing and implementing an "index of airway inflammation" based on objective findings.
